A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience - Study Protocol

Amir Anoshiravani, Homayoon Vahedi, Siavosh Nasseri-Moghaddam, Hafez Fakheri, Fariborz Mansour-Ghanaei, Iradj Maleki, Hasan Vosoghinia, Mohammad Reza Ghadir, Ahmad Hormati, Nayyereh Aminisani, Amir Reza Radmard, Bardia Khosravi, Bahar Saberzadeh-Ardestani, Masoud Malekzadeh, Sudabeh Alatab, Anahita Sadeghi, Sarvenaz Salahi, Ali Reza Sima, Reza Malekzadeh

Abstract


BACKGROUND:

The COVID-19 pandemic has affected the health care infrastructure dramatically, with abundant resources necessarily being redirected to COVID-19 patients and their care. Also, patients with chronic diseases like inflammatory bowel disease (IBD) may be affected in several ways during this pandemic.

METHODS:

 We used the Iranian registry of Crohn’s and colitis (IRCC) infrastructure. We called and sent messages to follow-up and support the care of all registered patients. Besides, we prepared and distributed educational materials for these patients and physicians to reduce the risk of COVID-19 infection. We risk-stratified them and prepared outpatient clinics and hospitalization guidance for IBD patients.

RESULTS:

 Of 13165 Iranian patients with IBD, 51 have been diagnosed as having COVID-19. IBD patients made 1920 hotline calls. Among the patients with suspicious presentations, 14 COVID-19 infections were diagnosed. Additionally, 1782 patients with IBD from five provinces actively phone-called among whom 28 definite cases were diagnosed.

CONCLUSIONS:

IBD patients' follow-up could help in diagnosing the affected IBD patients with COVID-19. Additionally, the performance of protective actions and preparing the patients and physicians for decisive proceedings are the principles of protection of IBD patients.


Keywords


Protocols, Care, Inflammatory bowel disease, COVID-19

Full Text:

PDF


DOI: http://dx.doi.org/10.15171/middle%20east%20j%20di.v12i4.2273

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.